Navigation Links
Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis

proteins and enzymes cannot be realized without FDA approval. Haemacure will continue identification work on its plasma discard and seek partnerships with pharmaceutical and biotechnology companies that would fund the development and clinical activities required to bring these proteins and enzymes to market and with which it would share sales revenues.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company focused on developing and commercializing premium human therapeutic proteins. Haemacure utilizes its proprietary plasma protein extraction technology to develop next generation products, including hemostats for surgical use. Haemacure's lead product candidate, Hemaseel(TM)HMN, an all-human fibrin sealant, is in late stage clinical development for biosurgical applications. The second product, an all-human thrombin, a component of fibrin sealant, also has applications as a stand-alone product in the expanding biosurgical market. Follow-on development will focus on biomaterial combinations and drug delivery in select therapeutic areas. Haemacure will develop partnerships to advance specialty proteins that it has recently identified in its plasma-derived intermediates to address the unmet medical needs of patients. Haemacure also operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, and changes to the competit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 8, 2011 Reportlinker.com announces that a new ... Global Sepsis Therapeutics Industry ... This report analyzes the worldwide markets for ... sales of drugs used in the direct treatment ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) ... (DAA) currently in Phase IIb development for hepatitis C, ... Most Interesting Infectious Disease Projects to Watch. ... Top 10 infectious disease project," said Kevin Eastwood, Anadys, ...
Cached Medicine Technology:Global Sepsis Therapeutics Industry 2Global Sepsis Therapeutics Industry 3Global Sepsis Therapeutics Industry 4Global Sepsis Therapeutics Industry 5Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch 2Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch 3Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch 4
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... and alleviates muscle soreness after exercise, according to ... Illinois at Chicago. , The study, reported online ... of Physical Medicine and Rehabilitation , also showed ... had not exercised, suggesting that massage has benefits ... activity. , Improved circulation and relief of muscle ...
(Date:4/17/2014)... cent of Canadians surveyed said they would participate in ... number of genetic conditions, only 80 per cent said ... would sequence their newborns, genomes.,Most newborns in North America ... or two of life in which a tiny amount ... for about five to 54 conditions, depending on the ...
(Date:4/17/2014)... status as the leading weapon against the deadly disease ... new research indicating it simply needs to be administered ... the cheap anti-malarial drug chloroquine in treating and preventing ... than half a million people each year around the ... resistance to chloroquine, but research carried out at the ...
(Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... blocks muscle growth, has shown promising results as a ... studies, where its inhibition led to increased muscle mass ... a myostatin inhibitor in patients, assessed its safety in ... well-tolerated. The study was published today in Annals of ...
... in Boone County to house world class research, center in country,s ... of personalized medicine into mainstream ... ... MHS ), joined by Indiana Gov. Mitch Daniels, broke,ground today on its ...
... Holdings Corp.,(Nasdaq: HMSY ) today announced that it ... which will be held March 26-27, 2008 at the ... of HMS Holdings Corp., will,present on Wednesday, March 26th ... HMSY ) is a national leader in cost,containment ...
... hospitals will aggravate existing problems, ... ... state legislators to reject a proposal to,eliminate the state,s planning process for ... huge cuts in,funding to care for the elderly and poor, and already ...
... recurrent or new tumors by more than half, study found ... good news for the 60 percent of women with breast ... inhibitor (AI) drug letrozole (Femara) can cut risk of a ... even when women initiated the drug one to seven years ...
... &,Johnson will participate in the Eleventh Annual Lehman ... the Loews Miami Beach Hotel,in Miami, Florida. Dominic ... represent the Company in a session scheduled at,11:15 ... available to investors and other interested parties,by accessing ...
Cached Medicine News:Health News:New potential treatment for muscular dystrophy appears to be safe 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 3Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 4Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 5Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 2Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 3Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: